OSLO, NORWAY--(Marketwire - February 18, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its fourth quarter and full year 2012 results on Thursday, 28 February 2013. A presentation by Algeta’s senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET. The presentation will also be webcast live and can be accessed through www.algeta.com where questions can also be submitted during the presentation.
The presentation will take place at 10:00 CET at:
Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.
Algeta’s senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).
To participate in the conference call, please dial the appropriate number below five minutes prior to the call:
US: +1 877 423 0830
UK: +44 20 7153 9154
Norway: +47 21 06 61 13
Sweden: +46 8-506 443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44 580 65 22
Participant pin code: 434633#
To access the replay, please dial:
US: +1 877 679 2989
UK: +44 20 3364 5196
Norway: +47 23 50 02 03
Sweden: +46 8-505 564 73
Conference reference: 345360#
A replay version of the conference call will also be available at www.algeta.com.
The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
Press release:
http://hugin.info/134655/R/1678620/547936.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1678620]
For further information, please contact:
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
Email Contact
Media enquiries:
Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson
Email Contact
Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton
Email Contact
Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications
Email Contact
US investor enquiries:
Tricia Swanson
+1 646 378 2953
The Trout Group
Email Contact
